NEW YORK, Nov. 25, 2014 /PRNewswire/ -- Analyst Report by Small Cap IR - Tenax Therapeutics, Inc. (NASDAQ: TENX) After a name change and a refocus of priorities the Company is poised to strengthen its position as an emerging providers of products for the critical care market. In our view this lowers the risk profile and improves the odds of stock appreciation going forward.
Tenax Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of a portfolio of products for the critical care market in the United States and Canada. The key compound in the products is levosimendan, 2.5 mg/ml concentrate for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. Levosimendan has been granted Fast Track status, and the U.S. Food and Drug Administration (FDA) has also agreed to the protocol design under a Special Protocol Assessment (SPA), and provided guidance that a single successful trial will be sufficient to support approval of levosimendan in this indication. The trial is being conducted by Duke University's Duke Clinical Research Institute.
The analyst report discusses in more detail the current fundamental and technical factors that are developing to drive the stock going forward. Technical insights, trading targets, support and resistance are provided that should be of interest to traders. Analyst summary with valuation is also included. There is no cost obligation required to view this report:
Copy and paste to browser may be required.
About Small Cap IR
Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.
3rd party chartered financial analysts (CFA's) provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Contact: [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/small-cap-ir-issues-tenax-therapeutics-analyst-report-large-validated-market-opportunity-inspires-12-price-target-300000665.html
SOURCE Small Cap IR